{
    "clinical_study": {
        "@rank": "3111", 
        "arm_group": [
            {
                "arm_group_label": "TMZ plus concurrent re-irradiation", 
                "arm_group_type": "Experimental", 
                "description": "TMZ plus concurrent re-irradiation"
            }, 
            {
                "arm_group_label": "TMZ alone", 
                "arm_group_type": "Experimental", 
                "description": "TMZ alone"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hope to improve overall median survival of patients with recurrent\n      Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five\n      treatments of re-irradiation."
        }, 
        "brief_title": "A Phase III Study of Re-Irradiation in Recurrent Glioblastoma", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "detailed_description": {
            "textblock": "This is a stratified study for patients with recurrent intracranial glioblastoma or\n      gliosarcoma previously treated with concurrent chemoradiation presenting radiographic\n      progression or recurrence of tumour. Patients are stratified by extent of resection, time to\n      re-irradiation and re-irradiation volume."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically-proven intracranial glioblastoma or gliosarcoma previously treated\n             with concurrent chemoradiation\n\n          -  radiographic evidence of tumour progression or recurrence\n\n          -  18 years or older\n\n          -  ECOG 0 - 2\n\n          -  signed informed consent form\n\n        Exclusion Criteria:\n\n          -  tumour progression or recurrence within 3 months of initial concurrent chemoradiation\n\n          -  6 or more cycles of TMZ administered following chemoradiation at initial diagnosis\n\n          -  more than one prior course of salvage chemo for recurrent disease\n\n          -  prior invasive malignancy (except non-melanomatous skin cancer) unless disease free\n             for greater or equal to 3 years\n\n          -  prior head or neck RT except for T1 glottic cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830101", 
            "org_study_id": "CCI-Patel-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TMZ plus concurrent re-irradiation", 
                    "TMZ alone"
                ], 
                "intervention_name": "TMZ plus concurrent re-irradiation", 
                "intervention_type": "Drug", 
                "other_name": "Temedol"
            }, 
            {
                "arm_group_label": [
                    "TMZ plus concurrent re-irradiation", 
                    "TMZ alone"
                ], 
                "description": "low-dose temozolomide daily for one year", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug", 
                "other_name": "Temedol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Temozolomide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "recurrent glioblastoma", 
            "re-irradiation", 
            "continuous low-dose temozolomide"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T6G 1Z2"
                }, 
                "name": "Cross Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma", 
        "overall_official": [
            {
                "affiliation": "Cross Cancer Institute", 
                "last_name": "Samir Patel, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tom Baker Cancer Centre", 
                "last_name": "Gerald Lim, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the overall median survival of the combination of continuous dose-intense temozolomide with or without re-irradiation in patients with recurrent glioblastoma.", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830101"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate time to radiographic progression or recurrence of tumour following treatment with continuous dose-intense temozolomide with or without re-irradiation.", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "AHS Cancer Control Alberta", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AHS Cancer Control Alberta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "This study will not be proceeding due to lack of funding from anticipated sources"
    }
}